Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.
M Karoui,
A Rullier,
Alain LUCIANI,
F Bonnetain,
ML Auriault,
A Sarran,
G Monges,
H Trillaud,
K Le Malicot,
V Leroy,
I Sobhani,
A Bardier,
R Moreau,
I Brindel,
JF Seitz,
S Taieb,
BMC Cancer 10/07/2015;15 : 511 10.1186/s12885-015-1507-3.
Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice.
A Wolfromm,
Christophe RODRIGUEZ,
M Michel,
A Habibi,
V Audard,
E Benayoun,
Olivier ROGIER,
Dominique CHALLINE,
O Chosidow,
JD Lelievre,
X Chevalier,
F Le Bras,
C Pautas,
M Imbert,
Jean-Michel PAWLOTSKY,
O Wagner-Ballon,
Br J Haematol. 01/07/2015;170(2) : 192-199 10.1111/bjh.13421 28/04/2015
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
S Larrat,
S Vallet,
S David-Tchouda,
A Caporossi,
J Margier,
C Ramiere,
C Scholtes,
S Haim-Boukobza,
AM Roque-Afonso,
B Besse,
E Andre-Garnier,
S Mohamed,
P Halfon,
A Pivert,
H Le Guillou-Guillemette,
F Abravanel,
M Guivarch,
V Mackiewicz,
O Lada,
T Mourez,
JC Plantier,
Y Baazia,
S Alain,
S Hantz,
V Thibault,
C Gaudy-Graffin,
D Bouvet,
A Mirand,
C Henquell,
J Gozlan,
G Lagathu,
C Pronier,
A Velay,
E Schvoerer,
P Trimoulet,
H Fleury,
Magali BOUVIER-ALIAS,
E Brochot,
G Duverlie,
S Maylin,
S Gouriou,
Jean-Michel PAWLOTSKY,
P Morand,
J Clin Microbiol. 01/07/2015;53(7) : 2195-2202 10.1128/JCM.03633-14. 29/04/2015
Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity.
I Archambeaud,
H Auble,
P Nahon,
L Planche,
G Fallot,
R Faroux,
J Gournay,
D Samuel,
S Kury,
Cyrille FERAY,
Liver Int. 01/07/2015;35(7) : 1872-1876 10.1111/liv.12767 21/01/2015
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
C Charpentier,
GQ Lee,
Christophe RODRIGUEZ,
B Visseaux,
A Storto,
C Fagard,
JM Molina,
C Katlama,
Y Yazdanpanah,
PR Harrigan,
D Descamps,
J Antimicrob Chemother 01/07/2015;70(7) : 2090-2096 10.1093/jac/dkv048. 08/03/2015
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
P Sultanik,
V Mallet,
S Lagaye,
A Casrouge,
C Dorival,
Y Barthe,
H Fontaine,
Christophe HEZODE,
E Mottez,
JP Bronowicki,
F Carrat,
I Theodorou,
L Abel,
E Gayat,
A Fontanet,
S Pol,
ML Albert,
Liver Int 01/07/2015;35(7) : 1833-1844 10.1111/liv.12759. 23/01/2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
D Jensen,
KE Sherman,
Christophe HEZODE,
S Pol,
S Zeuzem,
V De Ledinghen,
A Tran,
M ElKhashab,
ZH Younes,
M Kugelmas,
S Mauss,
G Everson,
V Luketic,
J Vierling,
L Serfaty,
M Brunetto,
J Heo,
D Bernstein,
F McPhee,
D Hennicken,
P Mendez,
E Hughes,
S Noviello,
J Hepatol. 01/07/2015;63(1) : 30-37 10.1016/j.jhep.2015.02.018. 19/02/2015
Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery.
C Lim,
P Compagnon,
M Sebagh,
C Salloum,
Julien CALDERARO,
Alain LUCIANI,
G Pascal,
A Laurent,
E Levesque,
U Maggi,
Cyrille FERAY,
D Cherqui,
D Castaing,
D Azoulay,
HPB (Oxford) 01/07/2015;17(7) : 611-623 10.1111/hpb.12416 16/05/2015
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Christophe HEZODE,
T Asselah,
KR Reddy,
T Hassanein,
M Berenguer,
K Fleischer-Stepniewska,
P Marcellin,
C Hall,
G Schnell,
T Pilot-Matias,
N Mobashery,
R Redman,
RA Vilchez,
S Pol,
Lancet 20/06/2015;385(9986) : 2502-2509 10.1016/S0140-6736(15)60159-3. 31/03/2015
